AbbVie accuses rival of stealing blockbuster ‘trade secrets’ as clock ticks down on biosimilar assault

Two years before the first biosimilars to megablockbuster Humira are expected to hit the US market, AbbVie is taking one developer to court over allegations it stole trade secrets to create its copycat version.